Charlotte Buvry1, Lucie Cassagnes2, Marielle Tekath2, Maxime Artigues2, Bruno Pereira3, Virginie Rieu1, Guillaume Le Guenno1, Anne Tournadre4, Marc Ruivard5, Vincent Grobost6. 1. Department of Internal Medicine, CHU Estaing, 1 Place Lucie et Raymond Aubrac, 63100, Clermont-Ferrand, France. 2. Radiology Department, Clermont-Ferrand University Hospital, CHU Gabriel Montpied, 58 Av. Montalembert, 63003, Clermont-Ferrand, France. 3. Biostatistics Unit, Clermont-Ferrand University Hospital, 63000, Clermont-Ferrand, France. 4. Rheumatology Department, Clermont-Ferrand University Hospital, CHU Gabriel Montpied, 58 Av. Montalembert, 63003, Clermont-Ferrand, France. 5. Department of Internal Medicine, CHU Estaing, 1 Place Lucie et Raymond Aubrac, 63100, Clermont-Ferrand, France; Clermont Université, Université d'Auvergne, EA 4681, PEPRADE, BP 10448, 63000, Clermont-Ferrand, France. 6. Department of Internal Medicine, CHU Estaing, 1 Place Lucie et Raymond Aubrac, 63100, Clermont-Ferrand, France. Electronic address: vgrobost@chu-clermontferrand.fr.
Abstract
OBJECTIVE: To determine whether anti-Ro52 antibodies are associated with ILD in pSS. METHODS: Retrospective study based on the presence or absence of anti-Ro52 antibodies in patients with pSS. Patients underwent chest HRCT at the time of diagnosis or during follow-up. RESULTS: Sixty-eight patients were included. Two groups were defined by the presence (n = 31) or absence (n = 37) of anti-Ro52 antibodies. ILD was significantly higher in the presence of anti-Ro52 (41.9%, n = 13) versus in the anti-Ro52-negative group (16.2%, n = 6; p = 0.019). Multivariate analysis adjusted for anti-SSA/Ro60, anti-SSB antibodies and rheumatoid factor status confirmed that anti-Ro52 antibodies positivity is a predictive factor for ILD (p = 0.01). Nonspecific interstitial pneumonia was the most common pattern of ILD (31.6%). The majority of patients were diagnosed with pSS simultaneously to ILD (52.6%). In the anti-Ro52-negative group, no patients develop ILD after 5 years of follow-up. CONCLUSION: In pSS, the risk of developing ILD is higher in the presence of anti-Ro52 antibodies. In patients with pSS and anti-Ro52 antibodies, a clinical screening and pulmonary functional tests with DLCO is necessary during the follow-up and should comprise chest HRCT if there is a decline in the DLCO or clinical symptoms or inspiratory crackles.
OBJECTIVE: To determine whether anti-Ro52 antibodies are associated with ILD in pSS. METHODS: Retrospective study based on the presence or absence of anti-Ro52 antibodies in patients with pSS. Patients underwent chest HRCT at the time of diagnosis or during follow-up. RESULTS: Sixty-eight patients were included. Two groups were defined by the presence (n = 31) or absence (n = 37) of anti-Ro52 antibodies. ILD was significantly higher in the presence of anti-Ro52 (41.9%, n = 13) versus in the anti-Ro52-negative group (16.2%, n = 6; p = 0.019). Multivariate analysis adjusted for anti-SSA/Ro60, anti-SSB antibodies and rheumatoid factor status confirmed that anti-Ro52 antibodies positivity is a predictive factor for ILD (p = 0.01). Nonspecific interstitial pneumonia was the most common pattern of ILD (31.6%). The majority of patients were diagnosed with pSS simultaneously to ILD (52.6%). In the anti-Ro52-negative group, no patients develop ILD after 5 years of follow-up. CONCLUSION: In pSS, the risk of developing ILD is higher in the presence of anti-Ro52 antibodies. In patients with pSS and anti-Ro52 antibodies, a clinical screening and pulmonary functional tests with DLCO is necessary during the follow-up and should comprise chest HRCT if there is a decline in the DLCO or clinical symptoms or inspiratory crackles.